Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3772192 | 0.91 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL3151919 | 0.90 | CYP11B1 (0.42) | MKNK1MKNK2CYP11B1CYP11B2 | |
| SCHEMBL3137070 | 0.90 | XDH (0.43) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL3146037 | 0.90 | MAP4K4 (0.45) | CHRNB2CHRNB1CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3155835 | 0.90 | CHRNB1 (0.44) | CHRNB2CHRNB1CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3154857 | 0.89 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL3141913 | 0.89 | XDH (0.42) | XDHSLC22A12 | |
| SCHEMBL3150649 | 0.89 | XDH (0.37) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL3142660 | 0.88 | MKNK1 (0.36) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL3141489 | 0.88 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324205-A1 | FLUID, FLUORINE-CONTAINING AND SINGLE-COMPONENT COMPOSITION | CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2010-12-16 | — | — | US | disclosed |
| EP-1979321-B9 | NOVEL PYRIDINYLAMINOALKYLENE- AND PYRIDINYLOXYALKYLENE-CYCLOPROPANAMINES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2010-02-17 | — | — | EP | disclosed |
| US-20090198000-A1 | Liquid fluorine-containing and two-component compositions for the surface treatment of mineral and non-mineral substrates | EVONIK DEGUSSA GMBH (DE) | 2009-08-06 | — | — | US | disclosed |
| EP-1979321-B1 | NOVEL PYRIDINYLAMINOALKYLENE- AND PYRIDINYLOXYALKYLENE-CYCLOPROPANAMINES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2009-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | CHRNA6, CHRNE, CHRNG | CHRNB2 18/4885CHRNA4 8/4885CHRNB1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.